Pulmatrix Inc Market Cap ($4.86 Million)
Market Cap & Net Worth: Pulmatrix Inc (PULM)
Pulmatrix Inc market cap. Pulmatrix Inc (NASDAQ:PULM) has a market capitalization of $4.86 Million ($4.86 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28576 globally and #5878 in its home market, demonstrating a -7.64% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pulmatrix Inc's stock price $1.33 by its total outstanding shares 3652285 (3.65 Million). Also see Pulmatrix Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Pulmatrix Inc Market Cap History (2015–2026)
Pulmatrix Inc market cap history from 2015 to 2026. Data shows change from $3.07 Billion to $4.86 Million (-44.88% CAGR). Check PULM live share price for real-time trading data and today's change.
Index Memberships
Pulmatrix Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #817 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2625 of 3165 |
Weight: Pulmatrix Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Pulmatrix Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pulmatrix Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Pulmatrix Inc equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
3.27x
Pulmatrix Inc's market cap is 3.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $430.97 Million | $835.00K | -$27.84 Million | 516.13x | N/A |
| 2017 | $1.03 Billion | $335.00K | -$18.06 Million | 3074.46x | N/A |
| 2018 | $175.38 Million | $153.00K | -$20.56 Million | 1146.29x | N/A |
| 2019 | $62.82 Million | $7.91 Million | -$20.60 Million | 7.94x | N/A |
| 2020 | $86.92 Million | $12.63 Million | -$19.31 Million | 6.88x | N/A |
| 2021 | $31.96 Million | $5.17 Million | -$20.17 Million | 6.18x | N/A |
| 2022 | $14.17 Million | $6.07 Million | -$18.73 Million | 2.33x | N/A |
| 2023 | $6.79 Million | $7.30 Million | -$14.12 Million | 0.93x | N/A |
| 2024 | $25.49 Million | $7.81 Million | -$9.56 Million | 3.27x | N/A |
Competitor Companies of PULM by Market Capitalization
Companies near Pulmatrix Inc in the global market cap rankings as of November 4, 2026. Also see PULM total assets for a full breakdown of the balance sheet.
Key companies related to Pulmatrix Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Pulmatrix Inc (2015–2026)
Market capitalization of Pulmatrix Inc from 2015 to today. Between 2015 and today, Pulmatrix Inc's market cap moved from $3.07 Billion to $ 4.86 Million, with a yearly change of -44.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.86 Million | -40.36% |
| 2025 | $8.14 Million | -68.05% |
| 2024 | $25.49 Million | +275.27% |
| 2023 | $6.79 Million | -52.06% |
| 2022 | $14.17 Million | -55.67% |
| 2021 | $31.96 Million | -63.23% |
| 2020 | $86.92 Million | +38.37% |
| 2019 | $62.82 Million | -64.18% |
| 2018 | $175.38 Million | -82.97% |
| 2017 | $1.03 Billion | +138.98% |
| 2016 | $430.97 Million | -85.95% |
| 2015 | $3.07 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Pulmatrix Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.86 Million USD |
| MoneyControl | $4.86 Million USD |
| MarketWatch | $4.86 Million USD |
| marketcap.company | $4.86 Million USD |
| Reuters | $4.86 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pulmatrix Inc
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.… Read more